Transaction Valued at $122.5M Establishes 20,000-Liter US Biologics Drug Substance Manufacturing Platform, Covering Development through Commercial Supply
TAIPEI, TAIWAN - 2 July 2026 - Bora Pharmaceuticals Co., Ltd. ("Bora" or "Bora Group"; TWSE: 6472; OTCQX: BORAY) today announced the completion of its acquisition of the GMP manufacturing operations of MacroGenics, Inc. (NASDAQ: MGNX) including its biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million through its wholly owned subsidiary Bora Biologics USA, LLC.. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.With the close of the transaction, Bora Group's biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, and one development facility in Zhubei, Taiwan.
"This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply," said Bobby Sheng, Chairman and CEO of Bora Group. "As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
With the addition of the Rockville facility, Bora Biologics supports more than 4 active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada and the UK with fully integrated QC and analytical capabilities.
At a glance
- Company
- Bora Pharmaceuticals Co., Ltd.
- Ticker
- TWSE: 6472, OTCQX: BORAY
- Announcement
- Acquisition
- Location
- Rockville, Maryland
Key figures
- Transaction consideration
- US $122.5 million
- U.S. single-use bioreactor capacity
- 20,000 liters
- Active commercial programs supported
- more than 4
- Completed GMP batches
- more than 120
- Planned integration period
- 12 to 18 months
People
- Bobby ShengChairman and CEO of Bora Group
Products and programs
Bora Group intends to integrate its US drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution.
Hashtag: #BoraPharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company's future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company's control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
In brief
Bora Pharmaceuticals says it has completed the $122.5 million acquisition of MacroGenics’ GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland, and a warehousing center in Frederick, Maryland. The transaction adds Rockville to Bora Biologics’ U.S. manufacturing network, which the company says now has 20,000 liters of single-use bioreactor capacity across sites in Rockville and San Diego. Bora also signed a long-term service agreement with MacroGenics. The company reports that the expanded platform supports more than four active commercial programs and has completed more than 120 GMP batches. Bora says it plans to integrate its U.S. drug substance capabilities with existing sterile drug product operations over the next 12 to 18 months.
Key takeaways
- Bora completed its acquisition of MacroGenics’ Rockville manufacturing operations and Frederick warehousing center for $122.5 million.
- Bora Biologics now reports 20,000 liters of U.S. single-use bioreactor drug substance capacity across Rockville and San Diego.
- Bora signed a long-term CDMO service agreement with MacroGenics as part of the transaction.
- The company plans to integrate U.S. drug substance operations with existing sterile drug product capabilities over 12 to 18 months.
